[go: up one dir, main page]

WO2005116659A3 - Compositions et methodes associees a la maladie d'alzheimer - Google Patents

Compositions et methodes associees a la maladie d'alzheimer Download PDF

Info

Publication number
WO2005116659A3
WO2005116659A3 PCT/US2005/017263 US2005017263W WO2005116659A3 WO 2005116659 A3 WO2005116659 A3 WO 2005116659A3 US 2005017263 W US2005017263 W US 2005017263W WO 2005116659 A3 WO2005116659 A3 WO 2005116659A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compositions
alzheimer
methods relating
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/017263
Other languages
English (en)
Other versions
WO2005116659A2 (fr
Inventor
David Lowe
Howard Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEURODX LLC
Original Assignee
NEURODX LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEURODX LLC filed Critical NEURODX LLC
Publication of WO2005116659A2 publication Critical patent/WO2005116659A2/fr
Publication of WO2005116659A3 publication Critical patent/WO2005116659A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions, des trousses et des méthodes pour diagnostiquer, caractériser et traiter la maladie d'Alzheimer (AD). L'invention concerne des polypeptides et de petites molécules non-peptidiques, identifiés comme différentiellement exprimés dans des échantillons obtenus à partir de sujets AD en comparaison à des échantillons obtenus à partir de sujets non-AD, pouvant être utilisés respectivement en tant que marqueurs polypeptidiques et que marqueurs de métabolite. Ces marqueurs peuvent être utilisés seuls ou combinés.
PCT/US2005/017263 2004-05-18 2005-05-18 Compositions et methodes associees a la maladie d'alzheimer Ceased WO2005116659A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57225804P 2004-05-18 2004-05-18
US60/572,258 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005116659A2 WO2005116659A2 (fr) 2005-12-08
WO2005116659A3 true WO2005116659A3 (fr) 2006-09-08

Family

ID=34975179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/017263 Ceased WO2005116659A2 (fr) 2004-05-18 2005-05-18 Compositions et methodes associees a la maladie d'alzheimer

Country Status (1)

Country Link
WO (1) WO2005116659A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273746A1 (en) * 2006-02-28 2014-02-20 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
CA2689848A1 (fr) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methodes permettant de diagnostiquer la demence et autres troubles neurologiques
EP2117527B1 (fr) 2007-02-08 2020-06-17 Med-Life Discoveries LP Composés pour utilisation dans le traitement de la démence senile de type alzheimer
CN113049696B (zh) * 2021-03-04 2022-03-18 首都医科大学宣武医院 一种诊断受试者是否患阿尔茨海默病的代谢产物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414336A (en) * 1981-01-28 1983-11-08 The Green Cross Corporation Method for preparing sample for use in endotoxin test
US20020104104A1 (en) * 1995-06-07 2002-08-01 Kate Dora Games Method for identifying alzheimer's disease therapeutics using transgenic animal models

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414336A (en) * 1981-01-28 1983-11-08 The Green Cross Corporation Method for preparing sample for use in endotoxin test
US20020104104A1 (en) * 1995-06-07 2002-08-01 Kate Dora Games Method for identifying alzheimer's disease therapeutics using transgenic animal models

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAKINO T: "Use of microtiter plates for latex agglutination immunoassay of serum alpha 2-macroglobulin.", ANNALS OF CLINICAL AND LABORATORY SCIENCE. APR 2001, vol. 31, no. 2, April 2001 (2001-04-01), pages 205 - 210, XP008053348, ISSN: 0091-7370 *
VAN GOOL D ET AL: "alpha 2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease.", NEUROBIOLOGY OF AGING. 1993 MAY-JUN, vol. 14, no. 3, May 1993 (1993-05-01), pages 233 - 237, XP002347247, ISSN: 0197-4580 *
ZHANG RULIN ET AL: "Mining biomarkers in human sera using proteomic tools.", PROTEOMICS. JAN 2004, vol. 4, no. 1, January 2004 (2004-01-01), pages 244 - 256, XP008034741, ISSN: 1615-9853 *

Also Published As

Publication number Publication date
WO2005116659A2 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
CA2602088C (fr) Marqueurs biologiques du cancer de l'ovaire et du cancer de l'endometre
WO2006020269A3 (fr) Biomarqueurs de maladie neurodegenerative
WO2007062090A3 (fr) Procedes et compositions lies a des analyses de lymphocytes b
WO2007086904A3 (fr) Compositions a utiliser dans l’identification d’adenovirus
WO2008089994A8 (fr) Utilisation de igfbp-7 dans l'évaluation d'une insuffisance cardiaque
WO2005107491A3 (fr) Chromatographie d'affinite multi-lectine et ses utilisations
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
WO2007103770A3 (fr) Compositions et procedes pour l'analyse du cancer du rein
WO2007011907A3 (fr) Anticorps d'alpha-synucleine et techniques associees
WO2007118222A3 (fr) Compositions pour l'identification de champignons
WO2007084264A3 (fr) Procedes d’imagerie myocardique
WO2006134390A3 (fr) Methode destinee a diagnostiquer une maladie neurodegenerative
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
DE602007011566D1 (en) Ankheit
WO2010021822A3 (fr) Découverte de biomarqueurs candidats d’apoptose in vivo par profilage global de sites de coupure de caspase
WO2006116127A3 (fr) Compositions a utiliser dans l'identification de bacteries
DK1866650T3 (da) Neurodegenerative markører for depression
WO2008089072A3 (fr) Méthode d'établissement de profils protéomiques pour le diagnostic et la surveillance d'états pathologiques, le criblage de compositions et la surveillance thérapeutique
WO2007028161A3 (fr) Procédés et compositions permettant d’identifier des biomarqueurs utiles au diagnostic et/ou au traitement d’états biologiques
WO2008034016A3 (fr) Dosages pour détecter des protéines à l'état natif et identifier des composés qui modulent la stabilité desdites protéines
WO2009020596A3 (fr) Liquide céphalorachidien embryonnaire (e-lcr), protéines issues du e-lcr et procédés et compositions associés
WO2007047408A3 (fr) Application de signature promac
WO2006090389A3 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
WO2006104912A3 (fr) Mutations de c-met dans le cancer du poumon
WO2007010379A3 (fr) Evaluation calorimetrique de micro-organismes et utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO R69(1) EPC FORM 1205A OF 23-02-2007

122 Ep: pct application non-entry in european phase